FDA Extends Review Timeline For Additional Indication For Antibiotic DORIBAX(TM)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline for the second New Drug Application for the antibiotic DORIBAX(TM) (doripenem for injection).

More: continued here

Filed under: Respiratory on March 15th, 2008